Table 2.
Phospho-RTK profiling results for canine primary urothelial carcinoma tumor samples and urothelial carcinoma cell lines
| Receptor tyrosine kinase | Urothelial carcinoma tumors n (%) | Urothelial carcinoma cell lines n (%) |
|---|---|---|
| PDGFRa | 1 (11%) | 1 (25%) |
| PDGFRb | 3 (33%) | 1 (25%) |
| KIT | 3 (33%) | 1 (25%) |
| Flt-3 | 2 (22%) | 0 (0%) |
| M-CSF R | 3 (33%) | 1 (25%) |
| VEGFR1 | 2 (22%) | 0 (0%) |
| VEGFR2 | 3 (33%) | 0 (0%) |
| VEGFR3 | 5 (56%) | 0 (0%) |
| EGFR | 9 (100%) | 4 (100%) |
| ErbB2 | 8 (89%) | 4 (100%) |
| ErbB3 | 3 (33%) | 2 (50%) |
| ErbB4 | 4 (44%) | 1 (25%) |
| FGFR1 | 4 (44%) | 1 (25%) |
| FGFR2 | 4 (44%) | 1 (25%) |
| FGFR3 | 4 (44%) | 1 (25%) |
| FGFR4 | 2 (22%) | 0 (0%) |
| Insulin R | 7 (78%) | 2 (50%) |
| c-RET | 3 (33%) | 1 (25%) |
| ROR1 | 8 (89%) | 4 (100%) |
| ROR2 | 8 (89%) | 3 (75%) |
| Tie-1 | 9 (100%) | 4 (100%) |
| Tie-2 | 7 (78%) | 3 (75%) |
The 22 most commonly observed phosphorylated receptor tyrosine kinases on the phospho-RTK Arrays are listed in the first column. The number of primary urothelial carcinoma tumors with the respective phosphorylated RTK is shown as a total and percentage of all tumors (n = 9). The number of primary urothelial carcinoma cell lines with the respective phosphorylated RTK is shown in the right column as a total and percentage of all cell lines (n = 5)